Drug intelligence / Profile preview

I2L

Development stage: Unknown
Modality: Peptides, Cell Therapies
Administration: Intravenous

Overview

I2L is an altered peptide ligand derived from the GP2 epitope of the HER-2/neu protein. It is utilized in an immunotherapy approach where it pulses ex vivo expanded dendritic cells (DCs). These pulsed DCs are then administered to patients to stimulate a specific immune response, particularly the generation of IFN-gamma-producing CD8+ T cells, targeting cancer cells that express the HER-2/neu protein. This therapeutic strategy has been investigated in a phase I/II clinical trial for metastatic breast cancer.

Other names: isoleucine to leucine

Beyond the preview

Go deeper on I2L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I2L.

Explore the full profile